Innate Pharma S.A.
IPHYF
$1.50
$0.139.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.43% | -34.33% | -7.85% | 14.72% | 3.04% |
| Total Depreciation and Amortization | -0.43% | -1.37% | 7.85% | -18.08% | -3.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.43% | -42.90% | 7.85% | 165.20% | -3.04% |
| Change in Net Operating Assets | -0.43% | 125.75% | -7.85% | -211.37% | -3.04% |
| Cash from Operations | 0.43% | 28.63% | -7.85% | -209.76% | 3.04% |
| Capital Expenditure | 0.42% | -45.59% | -7.87% | 47.05% | 3.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -0.43% | -94.18% | 7.85% | -17.12% | -3.04% |
| Cash from Investing | -0.43% | -95.35% | 7.85% | -16.73% | -3.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.02% | 0.00% | 1.33% | 0.00% |
| Issuance of Common Stock | 0.00% | -99.67% | 0.00% | 426.70% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.43% | -143.33% | 7.85% | 715.27% | 3.04% |
| Foreign Exchange rate Adjustments | -0.49% | -92.95% | 7.85% | 506.73% | 3.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.43% | -107.87% | -7.85% | -248.73% | 3.04% |